Lane Rodney J, Khin Nyan Y, Rogan Chris M, Magnussen John, Pavlakis Nick, Lane David M, Clarke Stephen
Macquarie University Hospital, Sydney, NSW, Australia.
Australian School of Advanced Medicine, Macquarie University, Sydney, NSW, Australia.
Ann Surg Oncol. 2016 Oct;23(11):3699-3708. doi: 10.1245/s10434-016-5198-z. Epub 2016 Mar 25.
The authors herein describe a novel method of repeatable hepatic isolation using an implantable access system allowing simultaneous control of hepatic arterial and portal flows by multiple endovascular catheters.
The aim of this study was to assess the feasibility and safety of the system and to compress standard intravenous chemotherapy into 4 weeks of targeted intra-arterial delivery.
An arterial access system was implanted to the axillary artery via an anastomosis. Infusions of oxaliplatin were performed biweekly for 4 weeks, using balloon catheters to achieve hepatic isolation and segmental selectivity for 20-25 min. Fifty-seven treatments under general anesthetic were performed in ten patients with inoperable chemotherapy-refractory metastatic colorectal cancer. Systemic, intrahepatic, and hepatic venous pressures were recorded to assess vascular isolation, and platinum levels were measured to assess chemotherapy distribution.
Pressure verified, multiple day-only hepatic vascular isolation infusions were achieved in nine of ten patients, with a single patient receiving multiple hepatic arterial infusions. Positron emission tomography-computed tomography (PET-CT) imaging confirmed partial response in three of ten patients and stable disease in three of ten patients. Systemic toxicity was minimal as all treatment-related gastrointestinal and neuropathic symptoms reported throughout the 4 weeks were grades 1-2.
Intra-arterial chemotherapy infusions with hepatic vascular isolation can be achieved repeatedly with targeted selectivity and minimal complications using an implantable multicatheter access system. Oxaliplatin infusions over a 4-week period may achieve tumor response in selected patients in the salvage setting. The technique should be further assessed in a phase Ib/II study.
本文作者描述了一种使用可植入接入系统进行可重复肝脏隔离的新方法,该系统允许通过多个血管内导管同时控制肝动脉和门静脉血流。
本研究的目的是评估该系统的可行性和安全性,并将标准静脉化疗压缩至4周的靶向动脉内给药。
通过吻合术将动脉接入系统植入腋动脉。每两周进行一次奥沙利铂输注,持续4周,使用球囊导管实现肝脏隔离和节段选择性20 - 25分钟。对10例无法手术的化疗难治性转移性结直肠癌患者进行了57次全身麻醉下的治疗。记录全身、肝内和肝静脉压力以评估血管隔离情况,并测量铂水平以评估化疗分布。
10例患者中有9例实现了经压力验证的、仅在多天进行的肝血管隔离输注,1例患者接受了多次肝动脉输注。正电子发射断层扫描 - 计算机断层扫描(PET - CT)成像证实10例患者中有3例部分缓解,10例患者中有3例病情稳定。全身毒性最小,因为在整个4周内报告的所有与治疗相关的胃肠道和神经病变症状均为1 - 2级。
使用可植入多导管接入系统,可通过靶向选择性和最小并发症反复实现肝血管隔离下的动脉内化疗输注。在4周内输注奥沙利铂可能使选定的挽救治疗患者出现肿瘤反应。该技术应在Ib/II期研究中进一步评估。